Search for more clinical trials
Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy
Conditions
Cervical Cancer
Conditions: official terms
Uterine Cervical Neoplasms
Conditions: Keywords
cervical adenocarcinoma, cervical adenosquamous cell carcinoma, cervical squamous cell carcinoma, stage IA cervical cancer, stage IB cervical cancer, stage IIA cervical cancer
Study Type
Interventional
Study Phase
Phase 3
Study Design
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Intervention
Name: carboplatin
Type: Drug
Name: cisplatin
Type: Drug
Name: paclitaxel
Type: Drug
Overall Status
Recruiting
Summary
RATIONALE: Drugs used in chemotherapy, such as cisplatin, paclitaxel, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. It is not yet known whether chemotherapy and radiation therapy are more effective when given with or without additional chemotherapy in treating cervical cancer.
PURPOSE: This randomized phase III trial is studying chemotherapy and pelvic radiation therapy to see how well they work when given with or without additional chemotherapy in treating patients with high-risk early-stage cervical cancer after radical hysterectomy.
PURPOSE: This randomized phase III trial is studying chemotherapy and pelvic radiation therapy to see how well they work when given with or without additional chemotherapy in treating patients with high-risk early-stage cervical cancer after radical hysterectomy.
Detailed Description
OBJECTIVES:
Primary
- To determine if administering adjuvant systemic chemotherapy after chemoradiotherapy will improve disease-free survival compared to chemoradiotherapy alone in patients with high-risk early-stage cervical carcinoma found to have positive nodes and/or positive parametria after radical hysterectomy.
Secondary
- To evaluate adverse events.
- To evaluate overall survival.
- To evaluate quality of life.
- To evaluate chemotherapy-induced neuropathy.
- To perform a post-hoc dose-volume evaluation between patients treated with standard radiotherapy and patients treated with intensity-modulated radiotherapy (IMRT) with respect to toxicity and local control.
- To collect fixed tissue samples to identify tumor molecular signatures that may be associated with patient outcomes, such as adverse events, disease-free survival, and overall survival.
- To collect blood samples to identify secreted factors from serum and plasma that may be associated with adverse events or outcome and to identify single nucleotide polymorphisms (SNPs) in genes from buffy coat that may be associated with a genetic predisposition to tumor formation itself or a response to cytotoxic therapy.
OUTLINE: This is a multicenter study. Patients are stratified according to planned use of brachytherapy (no vs. yes), radiotherapy modality - [standard external beam radiotherapy (EBRT) vs. intensity-modulated radiotherapy (IMRT)], and radiotherapy dose (45 Gy vs. 50.4 Gy). Patients are randomized to 1 of 2 treatment arms.
- Arm I: Patients undergo standard EBRT or IMRT to the pelvis once daily 5 days a week for 5-6 weeks. Patients also receive concurrent cisplatin IV over 1 hour once weekly for 6 weeks.
NOTE: Some patients may also undergo brachytherapy beginning within 7 days after completion of radiotherapy.
- Arm II: Patients receive chemoradiotherapy as in arm I. Beginning 4-6 weeks after completion of chemoradiotherapy, patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
Quality of life is assessed by the Functional Assessment of Cancer Therapy - Gynecologic Oncology Group (FACT-GOG/NTX4), FACT-Cx, and FACIT-D questionnaires at baseline; at the completion of chemoradiotherapy; and then at 6, 12, and 24 months after completion of chemoradiotherapy.
Blood and tissue samples may be collected for gene expression analysis by immuno-histochemistry (IHC) and for biomarker and polymorphism studies.
After completion of study treatment, patients are followed up very 3 months for 2 years, every 6 months for 3 years, and then annually thereafter.
Primary
- To determine if administering adjuvant systemic chemotherapy after chemoradiotherapy will improve disease-free survival compared to chemoradiotherapy alone in patients with high-risk early-stage cervical carcinoma found to have positive nodes and/or positive parametria after radical hysterectomy.
Secondary
- To evaluate adverse events.
- To evaluate overall survival.
- To evaluate quality of life.
- To evaluate chemotherapy-induced neuropathy.
- To perform a post-hoc dose-volume evaluation between patients treated with standard radiotherapy and patients treated with intensity-modulated radiotherapy (IMRT) with respect to toxicity and local control.
- To collect fixed tissue samples to identify tumor molecular signatures that may be associated with patient outcomes, such as adverse events, disease-free survival, and overall survival.
- To collect blood samples to identify secreted factors from serum and plasma that may be associated with adverse events or outcome and to identify single nucleotide polymorphisms (SNPs) in genes from buffy coat that may be associated with a genetic predisposition to tumor formation itself or a response to cytotoxic therapy.
OUTLINE: This is a multicenter study. Patients are stratified according to planned use of brachytherapy (no vs. yes), radiotherapy modality - [standard external beam radiotherapy (EBRT) vs. intensity-modulated radiotherapy (IMRT)], and radiotherapy dose (45 Gy vs. 50.4 Gy). Patients are randomized to 1 of 2 treatment arms.
- Arm I: Patients undergo standard EBRT or IMRT to the pelvis once daily 5 days a week for 5-6 weeks. Patients also receive concurrent cisplatin IV over 1 hour once weekly for 6 weeks.
NOTE: Some patients may also undergo brachytherapy beginning within 7 days after completion of radiotherapy.
- Arm II: Patients receive chemoradiotherapy as in arm I. Beginning 4-6 weeks after completion of chemoradiotherapy, patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
Quality of life is assessed by the Functional Assessment of Cancer Therapy - Gynecologic Oncology Group (FACT-GOG/NTX4), FACT-Cx, and FACIT-D questionnaires at baseline; at the completion of chemoradiotherapy; and then at 6, 12, and 24 months after completion of chemoradiotherapy.
Blood and tissue samples may be collected for gene expression analysis by immuno-histochemistry (IHC) and for biomarker and polymorphism studies.
After completion of study treatment, patients are followed up very 3 months for 2 years, every 6 months for 3 years, and then annually thereafter.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: N/A
Minimum Age: 18 Years
Gender: Female
Criteria: DISEASE CHARACTERISTICS:
- Histologically confirmed squamous, adenosquamous, or adenocarcinoma of the cervix with any/all of the following high-risk features after surgery:
- Positive pelvic nodes
- Positive parametrium
- Positive para-aortic nodes that have been completely resected and are PET/CT scan-negative
- PET only required if positive para-aortic nodes during surgery
- Clinical stage IA2, IB, or IIA disease (this corresponds to surgical tumor node metastasis (TNM) staging of T1-T2, N1, M0)
- Must have undergone radical hysterectomy (open, laparoscopically, or robotic) and staging within the past 70 days
- Para-aortic and pelvic node sampling required
- If the patient did not have a para-aortic lymph node sampling/dissection, but had common iliac node dissection that was negative, a PET-CT is recommended, but not required
- A negative pre- or post-operative PET scan or PET-CT scan of the para-aortic nodes is required if the patient did not undergo para-aortic or common iliac nodal sampling/dissection
- No gross residual disease
- No neuroendocrine histology
- No distant metastases
PATIENT CHARACTERISTICS:
- Zubrod performance status 0-1
- Absolute neutrophil count (ANC) ≥ 1,800/mm³
- Platelets ≥ 100,000/mm³
- White blood cell count (WBC) ≥ 4,000/mm³
- Hemoglobin ≥ 10.0 g/dL (transfusion or other intervention allowed)
- Serum creatinine ≤ 1.5 mg/dL
- Bilirubin ≤ 1.5 times upper limit of normal
- Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) normal
- Alkaline phosphatase normal
- Known HIV positivity allowed provided cluster of differentiation 4 (CD4) count is ≥ 350/mm³ within the past 14 days
- No other invasive malignancy within the past 3 years, except nonmelanomatous skin cancer or carcinoma in situ of the breast, oral cavity, or cervix
- No severe, active co-morbidity, including any of the following:
- Unstable angina and/or congestive heart failure requiring hospitalization within the past 6 months
- Transmural myocardial infarction within the past 6 months
- Acute bacterial or fungal infection requiring IV antibiotics at the time of study entry
- Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of study entry
- Coagulation defects
- No prior allergic reaction to carboplatin, paclitaxel, and/or cisplatin
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- No prior systemic chemotherapy for the current cervical cancer
- Prior chemotherapy for a different cancer is allowed
- No prior radiotherapy to the pelvis that would result in overlap of radiotherapy fields
- Histologically confirmed squamous, adenosquamous, or adenocarcinoma of the cervix with any/all of the following high-risk features after surgery:
- Positive pelvic nodes
- Positive parametrium
- Positive para-aortic nodes that have been completely resected and are PET/CT scan-negative
- PET only required if positive para-aortic nodes during surgery
- Clinical stage IA2, IB, or IIA disease (this corresponds to surgical tumor node metastasis (TNM) staging of T1-T2, N1, M0)
- Must have undergone radical hysterectomy (open, laparoscopically, or robotic) and staging within the past 70 days
- Para-aortic and pelvic node sampling required
- If the patient did not have a para-aortic lymph node sampling/dissection, but had common iliac node dissection that was negative, a PET-CT is recommended, but not required
- A negative pre- or post-operative PET scan or PET-CT scan of the para-aortic nodes is required if the patient did not undergo para-aortic or common iliac nodal sampling/dissection
- No gross residual disease
- No neuroendocrine histology
- No distant metastases
PATIENT CHARACTERISTICS:
- Zubrod performance status 0-1
- Absolute neutrophil count (ANC) ≥ 1,800/mm³
- Platelets ≥ 100,000/mm³
- White blood cell count (WBC) ≥ 4,000/mm³
- Hemoglobin ≥ 10.0 g/dL (transfusion or other intervention allowed)
- Serum creatinine ≤ 1.5 mg/dL
- Bilirubin ≤ 1.5 times upper limit of normal
- Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) normal
- Alkaline phosphatase normal
- Known HIV positivity allowed provided cluster of differentiation 4 (CD4) count is ≥ 350/mm³ within the past 14 days
- No other invasive malignancy within the past 3 years, except nonmelanomatous skin cancer or carcinoma in situ of the breast, oral cavity, or cervix
- No severe, active co-morbidity, including any of the following:
- Unstable angina and/or congestive heart failure requiring hospitalization within the past 6 months
- Transmural myocardial infarction within the past 6 months
- Acute bacterial or fungal infection requiring IV antibiotics at the time of study entry
- Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of study entry
- Coagulation defects
- No prior allergic reaction to carboplatin, paclitaxel, and/or cisplatin
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- No prior systemic chemotherapy for the current cervical cancer
- Prior chemotherapy for a different cancer is allowed
- No prior radiotherapy to the pelvis that would result in overlap of radiotherapy fields
Locations
University of Alabama at Birmingham
Birmingham, Alabama, United States
Providence Hospital
Status: Active, not recruiting
Mobile, Alabama, United States
Providence Alaska Medical Center
Status: Terminated
Anchorage, Alaska, United States
Arizona Center for Cancer Care-Peoria
Status: Active, not recruiting
Peoria, Arizona, United States
Saint Joseph's Hospital and Medical Center
Status: Active, not recruiting
Phoenix, Arizona, United States
Providence Saint Joseph Medical Center/Disney Family Cancer Center
Status: Active, not recruiting
Burbank, California, United States
Roy and Patricia Disney Family Cancer Center
Status: Active, not recruiting
Burbank, California, United States
City of Hope Medical Center
Status: Withdrawn
Duarte, California, United States
Saint Joseph Hospital - Orange
Status: Active, not recruiting
Orange, California, United States
Pomona Valley Hospital Medical Center
Status: Active, not recruiting
Pomona, California, United States
Mercy General Hospital Radiation Oncology Center
Status: Active, not recruiting
Sacramento, California, United States
Radiological Associates of Sacramento
Status: Terminated
Sacramento, California, United States
Saint Helena Hospital
Status: Withdrawn
Saint Helena, California, United States
University of California At San Diego
Status: Active, not recruiting
San Diego, California, United States
University of Colorado Cancer Center - Anschutz Cancer Pavilion
Status: Active, not recruiting
Aurora, Colorado, United States
Penrose-Saint Francis Healthcare
Status: Withdrawn
Colorado Springs, Colorado, United States
Hartford Hospital
Status: Active, not recruiting
Hartford, Connecticut, United States
The Hospital of Central Connecticut
Status: Active, not recruiting
New Britain, Connecticut, United States
University of Miami Sylvester Comprehensive Cancer Center at Deerfield Beach
Status: Active, not recruiting
Deerfield Beach, Florida, United States
Memorial Healthcare System - Joe DiMaggio Children's Hospital
Status: Active, not recruiting
Hollywood, Florida, United States
Baptist Hospital of Miami
Status: Active, not recruiting
Miami, Florida, United States
Jackson Memorial Hospital-Holtz Children's Hospital
Status: Active, not recruiting
Miami, Florida, United States
University of Miami Miller School of Medicine-Sylvester Cancer Center
Status: Active, not recruiting
Miami, Florida, United States
Florida Hospital
Status: Active, not recruiting
Orlando, Florida, United States
Grady Health System
Status: Active, not recruiting
Atlanta, Georgia, United States
Northside Hospital
Status: Active, not recruiting
Atlanta, Georgia, United States
Northeast Georgia Medical Center
Status: Active, not recruiting
Gainesville, Georgia, United States
Memorial Health University Medical Center
Status: Active, not recruiting
Savannah, Georgia, United States
Saint Joseph's-Candler Health System
Status: Active, not recruiting
Savannah, Georgia, United States
Queen's Medical Center
Status: Active, not recruiting
Honolulu, Hawaii, United States
University of Hawaii
Status: Active, not recruiting
Honolulu, Hawaii, United States
Saint Alphonsus Regional Medical Center
Status: Active, not recruiting
Boise, Idaho, United States
Northwestern University
Status: Active, not recruiting
Chicago, Illinois, United States
Rush University Medical Center
Status: Active, not recruiting
Chicago, Illinois, United States
OSF Saint Francis Medical Center
Status: Active, not recruiting
Peoria, Illinois, United States
Saint Vincent Anderson Regional Hospital/Cancer Center
Status: Active, not recruiting
Anderson, Indiana, United States
Saint Francis Hospital and Health Centers
Status: Active, not recruiting
Beech Grove, Indiana, United States
Franciscan Saint Margaret Health-Hammond Campus
Status: Recruiting
Contact: David H. Moore - 317-851-2555
Hammond, Indiana, United States
Franciscan Saint Francis Health-Indianapolis
Status: Terminated
Indianapolis, Indiana, United States
Michiana Hematology Oncology PC-Mishawaka
Status: Active, not recruiting
Mishawaka, Indiana, United States
University of Iowa Hospitals and Clinics
Status: Active, not recruiting
Iowa City, Iowa, United States
Mercy Medical Center - North Iowa
Status: Active, not recruiting
Mason City, Iowa, United States
University of Kansas Medical Center
Status: Active, not recruiting
Kansas City, Kansas, United States
Kansas City Cancer Centers-Southwest
Status: Active, not recruiting
Overland Park, Kansas, United States
Via Christi Regional Medical Center
Status: Active, not recruiting
Wichita, Kansas, United States
Greater Baltimore Medical Center
Status: Active, not recruiting
Baltimore, Maryland, United States
Sinai Hospital of Baltimore
Status: Active, not recruiting
Baltimore, Maryland, United States
University of Maryland/Greenebaum Cancer Center
Status: Active, not recruiting
Baltimore, Maryland, United States
Central Maryland Radiation Oncology in Howard County
Status: Active, not recruiting
Columbia, Maryland, United States
Holy Cross Hospital
Status: Active, not recruiting
Silver Spring, Maryland, United States
Hickman Cancer Center
Status: Active, not recruiting
Adrian, Michigan, United States
Saint John Hospital and Medical Center
Status: Active, not recruiting
Detroit, Michigan, United States
Wayne State University/Karmanos Cancer Institute
Status: Active, not recruiting
Detroit, Michigan, United States
West Michigan Cancer Center
Status: Withdrawn
Kalamazoo, Michigan, United States
Saint Joseph Mercy Port Huron
Status: Active, not recruiting
Port Huron, Michigan, United States
Saint John Macomb-Oakland Hospital
Status: Active, not recruiting
Warren, Michigan, United States
Abbott-Northwestern Hospital
Status: Active, not recruiting
Minneapolis, Minnesota, United States
Mayo Clinic
Status: Active, not recruiting
Rochester, Minnesota, United States
University of Mississippi Medical Center
Status: Active, not recruiting
Jackson, Mississippi, United States
Kansas City Cancer Center - South
Status: Active, not recruiting
Kansas City, Missouri, United States
Kansas City Cancer Centers - North
Status: Active, not recruiting
Kansas City, Missouri, United States
Kansas City Cancer Center-Lee's Summit
Status: Active, not recruiting
Lee's Summit, Missouri, United States
Phelps County Regional Medical Center
Status: Active, not recruiting
Rolla, Missouri, United States
Saint John's Mercy Medical Center
Status: Active, not recruiting
Saint Louis, Missouri, United States
CoxHealth South Hospital
Status: Active, not recruiting
Springfield, Missouri, United States
Mercy Hospital Springfield
Status: Active, not recruiting
Springfield, Missouri, United States
Nebraska Methodist Hospital
Status: Active, not recruiting
Omaha, Nebraska, United States
The Nebraska Medical Center
Status: Active, not recruiting
Omaha, Nebraska, United States
Elliot Hospital
Status: Active, not recruiting
Manchester, New Hampshire, United States
Cooper Hospital University Medical Center
Status: Active, not recruiting
Camden, New Jersey, United States
Morristown Memorial Hospital
Status: Active, not recruiting
Morristown, New Jersey, United States
Fox Chase Cancer Center at Virtua Memorial Hospital of Burlington County
Status: Active, not recruiting
Mount Holly, New Jersey, United States
UMDNJ - New Jersey Medical School
Status: Active, not recruiting
Newark, New Jersey, United States
MD Anderson Cancer Center at Cooper-Voorhees
Status: Active, not recruiting
Voorhees, New Jersey, United States
Montefiore Medical Center
Status: Active, not recruiting
Bronx, New York, United States
Montefiore Medical Center-Weiler Division
Status: Active, not recruiting
Bronx, New York, United States
State University of New York Downstate Medical Center
Status: Active, not recruiting
Brooklyn, New York, United States
Memorial Sloan-Kettering Cancer Center
Status: Active, not recruiting
New York, New York, United States
Highland Hospital
Status: Active, not recruiting
Rochester, New York, United States
University of Rochester
Status: Active, not recruiting
Rochester, New York, United States
Carolinas Medical Center
Status: Active, not recruiting
Charlotte, North Carolina, United States
Akron General Medical Center
Status: Active, not recruiting
Akron, Ohio, United States
Summa Akron City Hospital/Cooper Cancer Center
Status: Active, not recruiting
Akron, Ohio, United States
Summa Barberton Hospital
Status: Active, not recruiting
Barberton, Ohio, United States
University of Cincinnati
Status: Active, not recruiting
Cincinnati, Ohio, United States
Case Western Reserve University
Status: Active, not recruiting
Cleveland, Ohio, United States
Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center
Status: Active, not recruiting
Columbus, Ohio, United States
Summa Health Center at Lake Medina
Status: Active, not recruiting
Medina, Ohio, United States
UHHS-Chagrin Highlands Medical Center
Status: Active, not recruiting
Orange Village, Ohio, United States
Southern Ohio Medical Center
Status: Active, not recruiting
Portsmouth, Ohio, United States
Robinson Radiation Oncology
Status: Active, not recruiting
Ravenna, Ohio, United States
Cancer Care Center, Incorporated
Status: Active, not recruiting
Salem, Ohio, United States
Ireland Cancer Center at Firelands Regional Medical Center
Status: Terminated
Sandusky, Ohio, United States
Flower Hospital
Status: Active, not recruiting
Sylvania, Ohio, United States
University of Toledo
Status: Active, not recruiting
Toledo, Ohio, United States
UHHS-Westlake Medical Center
Status: Active, not recruiting
Westlake, Ohio, United States
Cancer Treatment Center
Status: Active, not recruiting
Wooster, Ohio, United States
University of Oklahoma Health Sciences Center
Status: Terminated
Oklahoma City, Oklahoma, United States
Natalie Warren Bryant Cancer Center at Saint Francis
Status: Active, not recruiting
Tulsa, Oklahoma, United States
Providence Portland Medical Center
Status: Withdrawn
Portland, Oregon, United States
Providence Saint Vincent Medical Center
Status: Active, not recruiting
Portland, Oregon, United States
Delaware County Memorial Hospital
Status: Active, not recruiting
Drexel Hill, Pennsylvania, United States
Reading Hospital
Status: Active, not recruiting
West Reading, Pennsylvania, United States
Lankenau Hospital
Status: Active, not recruiting
Wynnewood, Pennsylvania, United States
Women and Infants Hospital
Status: Recruiting
Contact: Paul B. Gilman - 484-476-2649 - wellenbachj@mlhs.org
Providence, Rhode Island, United States
Rapid City Regional Hospital
Status: Active, not recruiting
Rapid City, South Dakota, United States
Sanford Cancer Center-Oncology Clinic
Status: Active, not recruiting
Sioux Falls, South Dakota, United States
University of Tennessee - Knoxville
Status: Recruiting
Contact: Miroslaw A. Mazurczak - 605-328-1367
Knoxville, Tennessee, United States
University of Texas Southwestern Medical Center
Status: Active, not recruiting
Dallas, Texas, United States
M D Anderson Cancer Center
Status: Active, not recruiting
Houston, Texas, United States
M D Anderson Cancer Center
Status: Recruiting
Contact: Ann H. Klopp - aklopp@mdanderson.org
Houston, Texas, United States
Methodist Hospital
Status: Active, not recruiting
Houston, Texas, United States
Intermountain Medical Center
Status: Active, not recruiting
Murray, Utah, United States
McKay-Dee Hospital Center
Status: Active, not recruiting
Ogden, Utah, United States
Dixie Medical Center Regional Cancer Center
Status: Active, not recruiting
Saint George, Utah, United States
Huntsman Cancer Institute/University of Utah
Status: Active, not recruiting
Salt Lake City, Utah, United States
Seattle Cancer Care Alliance
Status: Active, not recruiting
Seattle, Washington, United States
North Star Lodge Cancer Center at Yakima Valley Memorial Hospital
Status: Active, not recruiting
Yakima, Washington, United States
Wheeling Hospital
Status: Recruiting
Contact: Sean F. Cleary - 877-902-3324
Wheeling, West Virginia, United States
Saint Vincent Hospital
Status: Active, not recruiting
Green Bay, Wisconsin, United States
Aurora Saint Luke's Medical Center
Status: Active, not recruiting
Milwaukee, Wisconsin, United States
Froedtert and the Medical College of Wisconsin
Status: Active, not recruiting
Milwaukee, Wisconsin, United States
Aurora West Allis Medical Center
Status: Active, not recruiting
West Allis, Wisconsin, United States
McGill University Department of Oncology
Status: Active, not recruiting
Montreal, Quebec, Canada
Pamela Youde Nethersole Eastern Hospital
Status: Active, not recruiting
Chai Wan, Hong Kong
Seoul National University Bundang Hospital
Status: Active, not recruiting
Seongnam City, Kyeonggi-do, Korea, Republic of
Gangnam Severance Hospital
Status: Active, not recruiting
Seoul, Korea, Republic of
Korea Cancer Center Hospital
Status: Active, not recruiting
Seoul, Korea, Republic of
Seoul National University Hospital
Status: Active, not recruiting
Seoul, Korea, Republic of
Status: Active, not recruiting
Start Date
September 2009
Sponsors
Radiation Therapy Oncology Group
Source
Radiation Therapy Oncology Group
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page